Pharmaceuticals - Iran

Iran

In 2024, the projected revenue in the Pharmaceuticals market in Iran is expected to reach US$7.90bn.
The largest market within this market is Oncology Drugs, which is projected to have a market volume of US$1.55bn in 2024.
It is anticipated that the revenue will exhibit an annual growth rate of 5.80% (CAGR 2024-2028), resulting in a market volume of US$9.90bn by 2028.
In comparison to other countries, United States is expected to generate the highest revenue of US$636.90bn in 2024.
Iran's pharmaceutical market is experiencing a surge in domestic production and research, positioning the country as a key player in the Middle East.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Iran, a country in the Middle East, has seen a significant development in its Pharmaceuticals market in recent years.

Customer preferences: Iranians have become increasingly health-conscious and are now more inclined to use pharmaceutical products to treat their ailments. Customers are also more likely to purchase branded pharmaceutical products over generic ones due to a perception that branded products are of higher quality.

Trends in the market: The Iranian pharmaceuticals market has been growing at a steady pace in recent years. This growth can be attributed to several factors, including an increase in the country's population, an increase in the prevalence of chronic diseases, and an increase in government spending on healthcare. Additionally, the Iranian government has been working to reduce the country's reliance on imported pharmaceutical products by encouraging local production.

Local special circumstances: One of the unique aspects of the Iranian pharmaceuticals market is the country's reliance on local production. The Iranian government has been working to develop the local pharmaceutical industry in order to reduce the country's reliance on imported products. This has led to an increase in the number of domestic pharmaceutical companies and an increase in local production.

Underlying macroeconomic factors: The Iranian pharmaceuticals market is influenced by several macroeconomic factors. One of the most significant factors is the country's population growth. Iran has one of the largest populations in the Middle East, which has led to an increase in demand for pharmaceutical products. Additionally, the prevalence of chronic diseases such as diabetes and cancer has been increasing in Iran, which has also contributed to the growth of the pharmaceuticals market. Finally, government spending on healthcare has been increasing in recent years, which has led to an increase in demand for pharmaceutical products.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.